Table 1.
Baseline Demographics and Clinical Characteristics (Safety Population)
| PROMISE7‐1 (Episodic Migraine) | PROMISE7‐2 (Chronic Migraine) | |||||
|---|---|---|---|---|---|---|
| Eptinezumab 100 mg (n = 223) | Eptinezumab 300 mg (n = 224) | Placebo (n = 222) | Eptinezumab 100 mg (n = 356) | Eptinezumab 300 mg (n = 350) | Placebo (n = 366) | |
| Mean (SD) age, years | 40.0 (10.7) | 40.2 (11.7) | 39.9 (11.7) | 41.0 (11.7) | 41.0 (10.4) | 39.6 (11.3) |
| Mean (SD) BMI, kg/m2 | 29.4 (7.6) | 28.9 (7.1) | 29.6 (7.3) | 26.4 (5.0) | 26.2 (5.0) | 27.0 (5.6) |
| Sex, n (%) female | 179 (80.3) | 199 (88.8) | 186 (83.8) | 307 (86.2) | 314 (89.7) | 325 (88.8) |
| Race, n (%) | ||||||
| White | 196 (87.9) | 187 (83.5) | 181 (81.5) | 332 (93.3) | 322 (92.0) | 321 (87.7) |
| Black/African American | 17 (7.6) | 27 (12.1) | 30 (13.5) | 21 (5.9) | 23 (6.6) | 38 (10.4) |
| Asian | 1 (<1) | 1 (<1) | 2 (<1) | 1 (<1) | 1 (<1) | 1 (<1) |
| American Indian/Alaska Native | 0 | 2 (<1) | 1 (<1) | 1 (<1) | 1 (<1) | 1 (<1) |
| Native Hawaiian/Pacific Islander | 1 (<1) | 1 (<1) | 1 (<1) | 0 | 1 (<1) | 0 |
| Multiple races | 7 (3.1) | 5 (2.2) | 5 (2.3) | 1 (<1) | 2 (<1) | 4 (1.1) |
| Other | 1 (<1) | 1 (<1) | 2 (<1) | 0 | 0 | 1 (<1) |
| Mean years since migraine diagnosis | 17.4 | 18.2 | 16.9 | 18.3 | 19.0 | 17.0 |
| Mean (SD) migraine days/month† | 8.7 (2.8) | 8.6 (2.9) | 8.4 (2.7) | 16.1 (4.6) | 16.1 (4.8) | 16.2 (4.6) |
| Mean (SD) headache days/month† | 10.0 (3.0) | 10.1 (3.1) | 9.9 (2.8) | 20.4 (3.1) | 20.4 (3.2) | 20.6 (3.0) |
†
eDiary‐reported migraine and headache characteristics during the 28‐day screening period.
BMI = body mass index; SD = standard deviation.